Pesticides & Agrochemicals · Founded 2002 · www.bestagrolife.com · BSE 539660 · NSE BESTAGRO · ISIN INE052T01021
No Notes Added Yet
Business
Best Agrolife Ltd. is an Indian agrochemical company primarily engaged in the manufacturing and distribution of various crop protection products. Its core business model involves developing, formulating, and marketing a wide range of pesticides, including insecticides, herbicides, fungicides, and plant growth regulators. The company operates across the value chain, from producing technical-grade active ingredients to formulating them into finished products that are sold to farmers and distributors across India. It generates revenue through the sales of these agrochemical products, aiming to enhance agricultural productivity and protect crops from pests and diseases.
Revenue Mix
While specific percentage breakdowns are not provided, Best Agrolife's revenue typically stems from two main product categories:
Technical Grade Products: Manufacturing the active pharmaceutical ingredients (APIs) or technical-grade chemicals for various pesticides.
Formulations: Developing and marketing ready-to-use formulated pesticide products, which include insecticides, herbicides, fungicides, and plant growth regulators. The company focuses on a diverse portfolio to cater to different crop cycles and pest management needs across various agricultural regions in India.
Industry
The Indian Pesticides & Agrochemicals industry is highly competitive, characterized by the presence of large multinational corporations, established domestic players, and numerous smaller enterprises. It is heavily influenced by monsoon patterns, government agricultural policies, and commodity prices. Best Agrolife positions itself as a growing domestic player with a focus on R&D for new product registrations and backward integration for key technicals. It aims to differentiate through its diverse product portfolio, including proprietary formulations, and an expanding distribution network, competing on product efficacy, availability, and pricing within the Indian market.
MOAT
Best Agrolife's potential competitive advantages include:
Backward Integration: Manufacturing technical-grade active ingredients for certain products can reduce reliance on external suppliers, control costs, and ensure supply chain stability.
Product Portfolio & R&D: A diverse range of products, including new-generation chemistries and proprietary formulations, along with a focus on new product registrations, allows it to cater to evolving farmer needs and gain market share.
Regulatory Approvals: Obtaining necessary registrations and licenses for various pesticides is a significant entry barrier and provides a degree of protection for existing products.
Distribution Network: An expanding presence across key agricultural states in India through a network of distributors and dealers helps in wider product reach.
Growth Drivers
Key factors that can drive Best Agrolife's growth over the next 3-5 years include:
Increasing Crop Protection Demand: Growing awareness among farmers regarding crop protection, coupled with increasing intensity of farming and changing pest patterns, drives demand for agrochemicals.
New Product Launches: Introduction of novel molecules, patented formulations, and generic versions of off-patent global products can significantly boost sales.
Expansion of Distribution: Widening its reach into new geographical areas and strengthening existing channels will enhance market penetration.
Backward Integration: Further vertical integration can improve cost efficiencies and offer better control over the supply chain.
Export Market Opportunities: Tapping into international markets for both technicals and formulations can provide additional revenue streams and reduce dependence on the domestic market.
Government Support for Agriculture: Favorable agricultural policies, subsidies, and focus on increasing farm productivity in India.
Risks
Monsoon Dependency: The performance of the Indian agricultural sector, and consequently agrochemical demand, is highly dependent on timely and adequate monsoons.
Regulatory Changes: Strict government regulations regarding pesticide usage, bans on certain chemicals, and environmental clearances can impact product portfolios and operations.
Raw Material Price Volatility: Fluctuations in the prices of crude oil and other chemical intermediates can affect manufacturing costs and profitability.
Intense Competition: High competition from domestic and international players can lead to pricing pressures and margin erosion.
Counterfeit Products: The presence of counterfeit or spurious agrochemicals in the market can erode trust, impact sales, and tarnish brand reputation.
Environmental & Health Concerns: Increasing scrutiny over the environmental and health impacts of pesticides could lead to stricter regulations and public backlash.
Management & Ownership
Best Agrolife Ltd. is typically a promoter-driven company, common in India, where the founding family or individuals hold significant stakes and steer strategic direction. The management team would comprise professionals with experience in the chemical and agricultural sectors. The quality of management is critical for navigating the complex regulatory environment, fostering innovation, and expanding market reach. Ownership structure would primarily involve promoter holdings alongside institutional and public shareholders.
Outlook
Best Agrolife operates in an essential sector with long-term growth potential driven by India's agricultural needs and increasing awareness of crop protection. The company's focus on R&D, new product introductions, and backward integration provides avenues for growth and competitive positioning. However, its success remains highly susceptible to external factors such as monsoon patterns, raw material price volatility, and evolving regulatory landscapes. Intense competition within the Indian agrochemical market also presents a continuous challenge, demanding constant innovation and efficient operations to maintain and grow market share. A balanced approach to expanding its product portfolio, strengthening its distribution, and managing supply chain risks will be crucial for sustained performance.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 135 | 519 | 747 | 274 | 274 | 381 | 517 | 203 | 156 | 396 |
| Other Income | 1 | 3 | 1 | -0 | 1 | 4 | -2 | 1 | 1 | 2 |
| Total Income | 136 | 522 | 748 | 274 | 275 | 385 | 515 | 204 | 157 | 398 |
| Total Expenditure | 202 | 465 | 600 | 280 | 270 | 335 | 439 | 199 | 183 | 318 |
| Operating Profit | -66 | 58 | 148 | -6 | 5 | 50 | 76 | 5 | -26 | 80 |
| Interest | 15 | 16 | 16 | 16 | 17 | 14 | 13 | 15 | 12 | 15 |
| Depreciation | 11 | 10 | 10 | 11 | 12 | 10 | 10 | 10 | 10 | 10 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -92 | 32 | 121 | -33 | -24 | 26 | 52 | -20 | -48 | 55 |
| Provision for Tax | -20 | 11 | 27 | -9 | -2 | 6 | 14 | -7 | -11 | 14 |
| Profit After Tax | -72 | 21 | 95 | -24 | -22 | 20 | 39 | -13 | -37 | 41 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -72 | 21 | 95 | -24 | -22 | 20 | 39 | -13 | -37 | 41 |
| Adjusted Earnings Per Share | -2 | 0.6 | 2.7 | -0.7 | -0.6 | 0.6 | 1.1 | -0.4 | -1 | 1.1 |
| #(Fig in Cr.) | Mar 2017 | Mar 2018 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 99 | 129 | 905 | 1211 | 1746 | 1873 | 1814 | 1257 | 1272 |
| Other Income | 0 | 4 | 7 | 2 | 3 | 3 | 5 | 5 | 2 |
| Total Income | 99 | 133 | 913 | 1213 | 1748 | 1876 | 1819 | 1261 | 1274 |
| Total Expenditure | 98 | 132 | 854 | 1045 | 1432 | 1648 | 1614 | 1157 | 1139 |
| Operating Profit | 1 | 1 | 58 | 168 | 316 | 229 | 205 | 105 | 135 |
| Interest | 1 | 1 | 5 | 15 | 39 | 62 | 66 | 53 | 55 |
| Depreciation | 0 | 0 | 3 | 12 | 25 | 33 | 43 | 42 | 40 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 51 | 141 | 253 | 134 | 96 | 10 | 39 |
| Provision for Tax | 0 | 0 | 14 | 36 | 61 | 27 | 26 | 1 | 10 |
| Profit After Tax | -0 | -0 | 37 | 105 | 192 | 106 | 70 | 9 | 30 |
| Adjustments | -3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -3 | 2 | 37 | 105 | 192 | 106 | 70 | 9 | 30 |
| Adjusted Earnings Per Share | -0 | -0 | 1.1 | 3 | 5.4 | 3 | 2 | 0.3 | 0.8 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -31% | -10% | 7% | 0% |
| Operating Profit CAGR | -49% | -31% | 13% | 0% |
| PAT CAGR | -87% | -64% | -25% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -29% | -38% | -26% | 25% |
| ROE Average | 1% | 10% | 25% | 21% |
| ROCE Average | 5% | 12% | 23% | 21% |
| #(Fig in Cr.) | Mar 2017 | Mar 2018 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 54 | 56 | 130 | 330 | 527 | 647 | 758 | 769 |
| Minority's Interest | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 8 | 3 | 49 | 34 | 21 | 14 | 27 |
| Other Non-Current Liabilities | -1 | -0 | 6 | 20 | 22 | 41 | 40 | 27 |
| Total Current Liabilities | 62 | 44 | 243 | 618 | 904 | 1319 | 1148 | 862 |
| Total Liabilities | 116 | 109 | 381 | 1017 | 1487 | 2027 | 1959 | 1685 |
| Fixed Assets | 0 | 0 | 19 | 180 | 203 | 362 | 374 | 351 |
| Other Non-Current Assets | 32 | 3 | 5 | 7 | 66 | 78 | 23 | 18 |
| Total Current Assets | 83 | 106 | 355 | 830 | 1218 | 1587 | 1563 | 1316 |
| Total Assets | 116 | 109 | 381 | 1017 | 1487 | 2027 | 1959 | 1685 |
| #(Fig in Cr.) | Mar 2017 | Mar 2018 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 1 | 10 | 21 | 13 | 62 | 33 | 33 |
| Cash Flow from Operating Activities | -14 | -41 | 13 | -60 | -180 | 36 | 228 | 97 |
| Cash Flow from Investing Activities | -34 | 31 | 8 | -15 | -19 | -63 | -29 | 1 |
| Cash Flow from Financing Activities | 48 | 10 | -11 | 67 | 248 | -1 | -199 | -96 |
| Net Cash Inflow / Outflow | 0 | -0 | 10 | -8 | 49 | -29 | -0 | 2 |
| Closing Cash & Cash Equivalent | 1 | 0 | 21 | 13 | 62 | 33 | 33 | 34 |
| # | Mar 2017 | Mar 2018 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -0.03 | -0.01 | 1.12 | 2.95 | 5.42 | 3 | 1.97 | 0.25 |
| CEPS(Rs) | -0.02 | 0.03 | 1.21 | 3.29 | 6.11 | 3.92 | 3.18 | 1.42 |
| DPS(Rs) | 0.01 | 0.01 | 0.13 | 0.13 | 0.2 | 0.2 | 0.2 | 0.1 |
| Book NAV/Share(Rs) | 10.61 | 11.13 | 3.79 | 9.23 | 14.51 | 17.32 | 19.09 | 19.18 |
| Core EBITDA Margin(%) | 1.05 | -2.26 | 5.19 | 12.71 | 16.22 | 9.5 | 7.89 | 6.15 |
| EBIT Margin(%) | 1.22 | 0.79 | 5.63 | 11.94 | 15.09 | 8.26 | 6.38 | 3.88 |
| Pre Tax Margin(%) | 0.03 | 0.03 | 5.15 | 10.78 | 13.08 | 5.63 | 3.8 | 0.6 |
| PAT Margin (%) | -0.14 | -0.02 | 3.76 | 8.03 | 9.94 | 4.47 | 2.76 | 0.55 |
| Cash Profit Margin (%) | -0.07 | 0.1 | 4.06 | 8.94 | 11.2 | 5.85 | 4.45 | 3.1 |
| ROA(%) | -0.12 | -0.02 | 15.11 | 14.98 | 15.35 | 6.05 | 3.51 | 0.49 |
| ROE(%) | -0.28 | -0.05 | 42.05 | 46.31 | 45.65 | 18.83 | 10.83 | 1.31 |
| ROCE(%) | 2.25 | 1.6 | 48.89 | 41.87 | 35.07 | 16.95 | 13.37 | 5.42 |
| Receivable days | 108.83 | 92.68 | 30.93 | 54.16 | 57.07 | 62.51 | 74 | 118.16 |
| Inventory Days | 36.34 | 47.91 | 32.88 | 85.1 | 109.79 | 128.05 | 124.53 | 159.66 |
| Payable days | 116.23 | 83.28 | 42.32 | 83.11 | 85.42 | 113.55 | 159.19 | 179.22 |
| PER(x) | 0 | 0 | 26.48 | 20.21 | 12.6 | 10.19 | 8.72 | 49.3 |
| Price/Book(x) | 0.22 | 0.02 | 7.84 | 6.47 | 4.71 | 1.76 | 0.9 | 0.64 |
| Dividend Yield(%) | 0.29 | 3.8 | 0.45 | 0.22 | 0.29 | 0.65 | 1.16 | 0.81 |
| EV/Net Sales(x) | 0.1 | 0.15 | 1.08 | 1.93 | 1.66 | 0.89 | 0.54 | 0.61 |
| EV/Core EBITDA(x) | 7.91 | 16.23 | 16.69 | 13.97 | 9.14 | 7.27 | 4.77 | 7.37 |
| Net Sales Growth(%) | 0 | 30.29 | 600.89 | 33.72 | 44.18 | 7.31 | -3.15 | -30.74 |
| EBIT Growth(%) | 0 | -15.51 | 5312.29 | 180.52 | 87.32 | -32.78 | -17.42 | -60.99 |
| PAT Growth(%) | 0 | 82.75 | 0 | 182.56 | 83.41 | -44.69 | -34.23 | -87.31 |
| EPS Growth(%) | 0 | 82.75 | 0 | 163.29 | 83.41 | -44.68 | -34.23 | -87.31 |
| Debt/Equity(x) | 0.01 | 0.37 | 0.22 | 0.81 | 1.08 | 1.02 | 0.69 | 0.64 |
| Current Ratio(x) | 1.35 | 2.44 | 1.46 | 1.34 | 1.35 | 1.2 | 1.36 | 1.53 |
| Quick Ratio(x) | 1.26 | 2.11 | 0.83 | 0.61 | 0.56 | 0.48 | 0.69 | 0.77 |
| Interest Cover(x) | 1.03 | 1.04 | 11.72 | 10.32 | 7.51 | 3.14 | 2.47 | 1.18 |
| Total Debt/Mcap(x) | 0.03 | 23.26 | 0.03 | 0.12 | 0.23 | 0.58 | 0.77 | 0.99 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 50.1 | 50.1 | 50.1 | 50.44 | 50.44 | 50.44 | 50.44 | 50.44 | 50.44 | 50.44 |
| FII | 8.73 | 8.03 | 5.1 | 5.8 | 5.75 | 5.75 | 5.63 | 5.52 | 5.56 | 5.53 |
| DII | 2.54 | 2.68 | 2.75 | 2.75 | 2.75 | 2.11 | 2.11 | 2.11 | 2.13 | 2.13 |
| Public | 38.63 | 39.19 | 42.04 | 41.01 | 41.06 | 41.69 | 41.81 | 41.92 | 41.87 | 41.89 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.18 | 1.18 | 1.18 | 1.19 | 1.19 | 1.19 | 1.19 | 17.89 | 17.89 | 17.89 |
| FII | 0.21 | 0.19 | 0.12 | 0.14 | 0.14 | 0.14 | 0.13 | 1.96 | 1.97 | 1.96 |
| DII | 0.06 | 0.06 | 0.07 | 0.07 | 0.07 | 0.05 | 0.05 | 0.75 | 0.76 | 0.76 |
| Public | 0.91 | 0.93 | 0.99 | 0.97 | 0.97 | 0.99 | 0.99 | 14.87 | 14.85 | 14.86 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2.36 | 2.36 | 2.36 | 2.36 | 2.36 | 2.36 | 2.36 | 35.47 | 35.47 | 35.47 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -31% | -10% | +7% | — |
| Operating Profit CAGR | -49% | -31% | +13% | — |
| PAT CAGR | -87% | -64% | -25% | — |
| Share Price CAGR | -29% | -38% | -26% | +25% |
| ROE Average | +1% | +10% | +25% | +21% |
| ROCE Average | +5% | +12% | +23% | +21% |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 50.1 | 50.1 | 50.1 | 50.44 | 50.44 | 50.44 | 50.44 | 50.44 | 50.44 | 50.44 |
| FII | 8.73 | 8.03 | 5.1 | 5.8 | 5.75 | 5.75 | 5.63 | 5.52 | 5.56 | 5.53 |
| DII | 2.54 | 2.68 | 2.75 | 2.75 | 2.75 | 2.11 | 2.11 | 2.11 | 2.13 | 2.13 |
| Public | 38.63 | 39.19 | 42.04 | 41.01 | 41.06 | 41.69 | 41.81 | 41.92 | 41.87 | 41.89 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.18 | 1.18 | 1.18 | 1.19 | 1.19 | 1.19 | 1.19 | 17.89 | 17.89 | 17.89 |
| FII | 0.21 | 0.19 | 0.12 | 0.14 | 0.14 | 0.14 | 0.13 | 1.96 | 1.97 | 1.96 |
| DII | 0.06 | 0.06 | 0.07 | 0.07 | 0.07 | 0.05 | 0.05 | 0.75 | 0.76 | 0.76 |
| Public | 0.91 | 0.93 | 0.99 | 0.97 | 0.97 | 0.99 | 0.99 | 14.87 | 14.85 | 14.86 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2.36 | 2.36 | 2.36 | 2.36 | 2.36 | 2.36 | 2.36 | 35.47 | 35.47 | 35.47 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.